Python==3.7
RDKit==2020.09.1
quantitative estimation of drug-likeness
Bickerton, G., Paolini, G., Besnard, J. et al. Quantifying the chemical beauty of drugs. Nature Chem 4, 90–98 (2012). https://doi.org/10.1038/nchem.1243
Molecular mass less than 500 Dalton
High lipophilicity (expressed as LogP less than 5)
Less than 5 hydrogen bond donors
Less than 10 hydrogen bond acceptors
Molar refractivity should be between 40-130
“rule-of-four” (RO4) to evaluate PPI inhibitors
MW must be higher than 400;
ALogP must be higher than 4;
HBA must be higher than 4;
The number of rings (RING) must be higher than 4.
"Rule of Three (Ro3)" compliant fragments (fragment-likeness) Jhoti, H., Williams, G., Rees, D. et al. The 'rule of three' for fragment-based drug discovery: where are we now?. Nat Rev Drug Discov 12, 644 (2013). https://doi.org/10.1038/nrd3926-c1
This filter defines drug-likeness constraints as follows:
calculated log P is between -0.4 and 5.6,
molecular weight is between 160 and 480,
molar refractivity is between 40 and 130,
total number of atoms is between 20 and 70.
The Veber filter is a rule of thumb filter for orally active drugs described in Veber et. al., J Med Chem. 2002; 45(12): 2615-23.
Walters, W., Namchuk, M. Designing screens: how to make your hits a hit. Nat Rev Drug Discov 2, 259–266 (2003). https://doi.org/10.1038/nrd1063